|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/11/24 Acadia Pharmaceuticals Inc. 8-K:8 3/11/24 10:137K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 22K 5: R1 Document and Entity Information HTML 47K 7: XML IDEA XML File -- Filing Summary XML 11K 10: XML XBRL Instance -- d786050d8k_htm XML 15K 6: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 3: EX-101.LAB XBRL Labels -- acad-20240311_lab XML 55K 4: EX-101.PRE XBRL Presentations -- acad-20240311_pre XML 35K 2: EX-101.SCH XBRL Schema -- acad-20240311 XSD 12K 8: JSON XBRL Instance as JSON Data -- MetaLinks 12± 19K 9: ZIP XBRL Zipped Folder -- 0001193125-24-064791-xbrl Zip 11K
| 8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i March 11, 2024
Acadia Pharmaceuticals Inc.
(Exact name of Registrant as Specified in Its Charter)
| i Delaware | i 000-50768 | i 06-1376651 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| i 12830 El Camino Real, i Suite 400 i San Diego, i California |
i 92130 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: i (858) i 558-2871
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
| i Common Stock, par value $0.0001 per share | i ACAD | i The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01 | Other Events. |
On March 11, 2024, Acadia Pharmaceuticals Inc. (the “Company”) announced top-line results of the Company’s Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. The study did not meet its primary endpoint. The safety and tolerability profile of pimavanserin was consistent with previous clinical trials, showing a low rate of adverse events.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Acadia Pharmaceuticals Inc. | ||||||
| Dated: March 11, 2024 | By: | |||||
| Jennifer J. Rhodes | ||||||
| Executive Vice President, Chief Legal Officer & Secretary | ||||||
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 3/11/24 | None on these Dates | ||
| List all Filings | ||||